BRF
CRBP icon

B. Riley Financial’s Corbus Pharmaceuticals CRBP Stock Holding History

B. Riley Financial’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,714
Closed -$315K – 24
2025
Q4 		$315K Buy
+38,714
New +$478K 0.13% 14

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

B. Riley Financial's CRBP Position: Q1 2026 in Review

B. Riley Financial sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 38,714 shares — an estimated $315K sold.

B. Riley Financial first reported a position in CRBP in Q4 2025 and held it in 1 quarter. The position peaked at $315K in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • B. Riley Financial reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • B. Riley Financial sold 38,714 Corbus Pharmaceuticals shares in Q1 2026, an estimated $315K.
  • B. Riley Financial first reported a position in Corbus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • B. Riley Financial's Corbus Pharmaceuticals position peaked at $315K in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on B. Riley Financial's 13F filing for Q1 2026, filed 15 May 2026.